Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Pfizer ( NYSE:PFE ) , Bristol-Myers Squibb ( NYSE:BMY ) , Sanofi ( NASDAQ:SNY )
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA ( NASDAQ:SNY ) and Bristol-Myers Squibb Co ( NYSE:BMY ) of concealing critical information about the effectiveness of their blood-thinning medication Plavix.
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? - Bristol-Myers Squibb ( NYSE:BMY )
Bristol-Myers Squibb Co's ( NYSE:BMY ) short interest as a percent of float has risen 6.04% since its last report. According to exchange reported data, there are now 32.07 million shares sold short, which is 1.58% of all regular shares that are available for trading.
Investors Heavily Search Bristol Myers Squibb Company ( BMY ) : Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
James M. O'Brien Appointed Chief Financial Officer at Mesoblast - Mesoblast ( NASDAQ:MESO )
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( NASDAQ:MESO, ASX:MSB ) ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed ...
James M. O'Brien Appointed Chief Financial Officer at Mesoblast
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed ...
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb & Co. ( NYSE:BMY ) , in collaboration with Johnson & Johnson ( NYSE:JNJ ) , announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care ( conventional antiplatelet therapy ) for ...
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Why Is BioNTech Stock Falling Today? - Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Pfizer ( NYSE:PFE ) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE ( NASDAQ:BNTX ) . It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report.
Here's Why Bristol Myers Squibb ( BMY ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Healthcare Stocks Topping a 2025 List of Dividend Yields
Turn health into wealth with these three high-yielding dividend stocks.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Chinese drug developer Biokin postpones Hong Kong listing
Chinese drug developer Sichuan Biokin Pharmaceutical has postponed its Hong Kong share listing, which had been scheduled to begin on Monday, as enthusiasm for initial public offerings (IPOs) in the sector may be cooling, according to analysts.
Jim Cramer Is Backing Off Bristol-Myers; Baidu, Alibaba Are Good - Alibaba Gr Hldgs ( NYSE:BABA ) , Baidu ( NASDAQ:BIDU )
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is backing off on Bristol-Myers Squibb Company ( NYSE:BMY ) . On the earnings front, Bristol Myers Squibb, on Oct. 30, reported third-quarter 2025 revenues of $12.22 billion, beating the consensus of $11.81 billion, and a 3% increase ...
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch - Insight Molecular ( NASDAQ:IMDX )
On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay's head-to-head data continue to be favorable Preparing to rapidly expand beyond kidney into heart ...
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
6 of the best: the billion-dollar biotechs putting China on the map
The ferocity of China's biopharmaceutical investment boom this year - fuelled by record-breaking licensing of commercial rights to global giants after a three-year slump - may have surprised casual observers. But according to Helen Chen, one of the most respected analysts and advisers in China's ...
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
-- New preclinical data for PM577 in Wilson's Disease ( WD ) to be presented at AASLD. on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency ( AATD ).
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
-- New preclinical data for PM577 in Wilson's Disease ( WD ) to be presented at AASLD. on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency ( AATD ).
Bristol Myers Squibb Company ( BMY ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting
- CX-801 ( PROBODY® interferon alpha-2b ) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma ...
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting - CytomX Therapeutics ( NASDAQ:CTMX )
- CX-801 ( PROBODY® interferon alpha-2b ) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801's mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA® ( pembrolizumab ) -
Aquestive Therapeutics Announces Leadership Expansion to Support Growth - Tiziana Life Sciences ( NASDAQ:TLSA ) , Aquestive Therapeutics ( NASDAQ:AQST )
Changes strategically aligned to support planned launch of Anaphylm™ ( dibutepinephrine ) Sublingual Film, if approved by the FDA, and to accelerate the Company's ongoing development initiatives Matthew Davis, M.D., RPh will join immediately as Chief Development Officer
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Chatillion, France, November ...
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - DBV Technologies ( NASDAQ:DBVT )
DBV Technologies ( TRQX:DBVp ) , a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately.
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - BioNTech ( NASDAQ:BNTX )
BioNTech SE ( NASDAQ:BNTX ) reported a third-quarter per-share loss of 14 cents ( 12 cents in euros ) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings of 75 cents per share.
Unpacking the Latest Options Trading Trends in uniQure - uniQure ( NASDAQ:QURE )
Whales with a lot of money to spend have taken a noticeably bullish stance on uniQure. Looking at options history for uniQure ( NASDAQ:QURE ) we detected 53 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish ...
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' - Cleveland-Cliffs ( NYSE:CLF ) , Bristol-Myers Squibb ( NYSE:BMY )
On CNBC's "Halftime Report Final Trades," Cerity Partners' Jim Lebenthal picked Cleveland-Cliffs Inc. ( NYSE:CLF ) . On Friday, Goldman Sachs analyst Mike Harris maintained a Buy rating on Cleveland-Cliffs and raised the price target from $14.5 to $16. Don't forget to check out our premarket ...
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
BioNTech SE today reported financial results for the three and nine months ended September 30, 2025 and provide an update on its corporate progress.
Here's Why Avidity Biosciences Stock Soared This Week ( There's More to the Deal Than You Might Think )
Novartis is set to boost its developmental pipeline with this acquisition.
Bristol Myers' New Treatments Drive Q3 Beat - And The Company's Raising Its Outlook - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb Co. ( NYSE:BMY ) reported third-quarter 2025 revenues of $12.22 billion on Thursday, beating the consensus of $11.81 billion, a 3% increase year over year.
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Bristol Myers Squibb ( BMY ) Q3 Earnings and Revenues Surpass Estimates
Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of ...
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Phathom Pharmaceuticals ( NASDAQ:PHAT )
Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170-$175 million.
Equinix ( EQIX ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Oct. 29, 2025, 5:30 p.m. ETChief Executive Officer and President - Adair Fox-MartinContinue reading ...
Microsoft ( MSFT ) Q1 2026 Earnings Call Transcript
Image source: The Motley Fool.Oct. 29, 2025 at 5:30 p.m. ETChairman and Chief Executive Officer - Satya NadellaContinue reading ...
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) , will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time ( 3:00 p.m. CET ) on Tuesday, November 11, 2025 in New York City, U.S.
3 Dividend-Paying Drug Stocks to Buy at a Discount
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Halozyme Therapeutics ( HALO ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
Ahead of Bristol Myers ( BMY ) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
MAINZ, Germany, October 27, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m.
Why Is Avidity Biosciences Stock Skyrocketing Monday? - Avidity Biosciences ( NASDAQ:RNA ) , Novartis ( NYSE:NVS )
Avidity Biosciences, Inc. ( NASDAQ:RNA ) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG ( NYSE:NVS ) in a deal valued at $12 billion on a fully diluted basis. As per the deal, Avidity shareholders will receive $72.00 per share in cash at ...
